1. Home
  2. NKX vs PRME Comparison

NKX vs PRME Comparison

Compare NKX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen California AMT-Free Quality Municipal Income Fund

NKX

Nuveen California AMT-Free Quality Municipal Income Fund

HOLD

Current Price

$11.70

Market Cap

640.3M

Sector

Finance

ML Signal

HOLD

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.16

Market Cap

553.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKX
PRME
Founded
2002
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Medicinal Chemicals and Botanical Products
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
640.3M
553.2M
IPO Year
N/A
2022

Fundamental Metrics

Financial Performance
Metric
NKX
PRME
Price
$11.70
$3.16
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$7.56
AVG Volume (30 Days)
146.4K
2.6M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
4.37%
N/A
EPS Growth
N/A
18.18
EPS
N/A
N/A
Revenue
N/A
$4,632,000.00
Revenue This Year
N/A
$7.06
Revenue Next Year
N/A
$47.01
P/E Ratio
N/A
N/A
Revenue Growth
N/A
55.28
52 Week Low
$11.68
$2.67
52 Week High
$13.20
$6.94

Technical Indicators

Market Signals
Indicator
NKX
PRME
Relative Strength Index (RSI) 25.22 47.08
Support Level N/A $3.16
Resistance Level $12.49 $3.69
Average True Range (ATR) 0.09 0.23
MACD -0.04 -0.02
Stochastic Oscillator 12.28 21.05

Price Performance

Historical Comparison
NKX
PRME

About NKX Nuveen California AMT-Free Quality Municipal Income Fund

Nuveen California AMT-Free Quality Municipal Income Fund is a closed-end fixed income mutual fund. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Arizona individual income taxes and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. It invests across sectors such as healthcare, utilities, transportation, and housing.

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

Share on Social Networks: